Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib, Venetoclax, and Rituximab in Previously Untreated Follicular Lymphoma
NCT06471738Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, venetoclax and rituximab in follicular lymphoma (FL), sponsored by Chinese PLA General Hospital. Primary endpoint: Complete Response Rate. Started Jul 2024; status: recruiting.
02
Drugs
zanubrutinibvenetoclaxrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06471738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471738.